MySmarTrend
← Insider Monitor
Trevi Therapeutics, Inc. logo
TRVI

Trevi Therapeutics, Inc.

Nasdaq · Pharmaceutical Preparations

3
Insider trades
0
Congress trades

Company Overview

A concise company profile alongside the latest public filing activity.

Trevi Therapeutics is a clinical-stage biopharmaceutical company developing Haduvio (oral nalbuphine) as a treatment for chronic cough associated with conditions such as idiopathic pulmonary fibrosis and prurigo nodularis.

Industry
Pharmaceutical Preparations
Headquarters
New Haven, CT
Exchange
Nasdaq

Company profile sourced from SEC filings.

Corporate Insider Trades

Open-market purchases and sales by directors, officers, and other company insiders.

InsiderTypeValueDate
Heffernan Michael ThomasInsiderSell$316KSep 15, 2026
Heffernan Michael ThomasInsiderSell$276KSep 15, 2026
Heffernan Michael ThomasInsiderSell$2KSep 15, 2026

Source: SEC EDGAR Form 4 filings

Congressional Trades

Recent disclosures by members of the U.S. House and Senate.

No recent congressional disclosures found for TRVI.

Source: Senate eFD and House Clerk STOCK Act disclosures

Get notable TRVI activity by email

Free alerts for the insider and congressional trades worth watching.

By submitting your email address, you will receive a free subscription to the MySmarTrend e-letter, and offers from us and our affiliates that we think might interest you. You can unsubscribe at any time. Privacy Policy.

For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.